Rein Therapeutics director buys shares, gets options
Rein Therapeutics, Inc. director and officer James Brian Windsor reported both a stock purchase and a new option grant.
Rhea-AI Filing Summary
Rein Therapeutics, Inc. director and officer James Brian Windsor reported both a stock purchase and a new option grant. On April 30, 2026, he bought 25,000 shares of common stock at $1.00 per share in the company’s follow-on public offering, bringing his direct common stock holdings to 27,046 shares.
On May 8, 2026, he received a stock option covering 150,000 shares of common stock at an exercise price of $1.17 per share, expiring on May 8, 2036. Twenty-five percent of the option is scheduled to vest on May 8, 2027, with the remainder vesting in equal monthly installments through May 8, 2031.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 25,000 shares
Net Buy
2 txns
Insider
WINDSOR JAMES BRIAN
Role
See Remarks
Bought
25,000 shs ($25K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 150,000 | $0.00 | $0.00 |
| Purchase | Common stock , $0.001 par value | 25,000 | $1.00 | $25K |
Holdings After Transaction:
Stock Option (Right to Buy) — 150,000 contracts (Direct);
Common stock , $0.001 par value — 27,046 shares (Direct)
Footnotes (2)
- F1. Shares purchased in Issuer's April 30, 2026 follow-on public offering.
- F2. This option was granted on May 8, 2026. The 25% of the shares underlying the option are scheduled to vest on May 8, 2027 and thereafter in equal monthly installments through May 8, 2031.
Key Figures
Common shares purchased: 25,000 shares at $1.00
Common shares held after purchase: 27,046 shares
Option grant size: 150,000 shares
+3 more
6 metrics
Common shares purchased
25,000 shares at $1.00
Open-market/offer purchase on April 30, 2026
Common shares held after purchase
27,046 shares
Direct ownership after April 30, 2026 transaction
Option grant size
150,000 shares
Stock option granted May 8, 2026
Option exercise price
$1.17 per share
Exercise price for 150,000-share option
Option expiration
May 8, 2036
Expiry date of stock option grant
Initial cliff vesting
25% on May 8, 2027
First vesting milestone for option
Key Terms
follow-on public offering, Stock Option (Right to Buy), exercise price, vesting
4 terms
follow-on public offering financial
"Shares purchased in Issuer's April 30, 2026 follow-on public offering."
An offering of new shares by a company that has already gone public, sold to investors to raise additional cash. Like a bakery cutting a larger cake to serve more customers, it increases the number of shares available which can lower each existing share’s claim on profits and ownership; investors watch these offerings because they can dilute current holdings, signal fundraising needs or growth plans, and often affect the stock price in the short term.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 1.1700"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"shares underlying the option are scheduled to vest on May 8, 2027 and thereafter in equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What insider transactions did Rein Therapeutics (RNTX) report for James Brian Windsor?
Rein Therapeutics reported that director and officer James Brian Windsor bought 25,000 common shares at $1.00 each and received a stock option for 150,000 shares at a $1.17 exercise price, both increasing his direct economic exposure to the company.
At what price did the Rein Therapeutics (RNTX) insider buy common stock?
James Brian Windsor purchased 25,000 Rein Therapeutics common shares at $1.00 per share. The footnote states these shares were bought in the company’s April 30, 2026 follow-on public offering, indicating participation in a capital-raising transaction rather than a secondary market trade.
What are the key terms of the Rein Therapeutics (RNTX) stock option granted to James Brian Windsor?
Windsor received a stock option for 150,000 Rein Therapeutics common shares at a $1.17 exercise price. The option was granted May 8, 2026, expires May 8, 2036, and vests 25% on May 8, 2027, with remaining shares vesting monthly through May 8, 2031.
How does the vesting schedule work for the Rein Therapeutics (RNTX) option grant?
The option vests over several years. Twenty-five percent of the 150,000 shares is scheduled to vest on May 8, 2027. The remaining 75% vests in equal monthly installments through May 8, 2031, aligning Windsor’s incentives with longer-term company performance.
AI-generated analysis. How Rhea-AI works. Not financial advice.
